{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:54Z","timestamp":1791928974026,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eplepsyres.2026.107731","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:24:37Z","timestamp":1768235077000},"page":"107731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4293","authenticated-orcid":false,"given":"Antonietta","family":"Coppola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Moore-Ramdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Navetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debopam","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2026.107731_bib1","unstructured":"Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica, 2023. ANMAT Disposici\u00f3n N\u00ba 3782-23, Convupidiol. Accessed 22 September 2025. https:\/\/boletin.anmat.gob.ar\/mayo_2023\/Dispo_3782-23.pdf."},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107731_bib2","first-page":"107","article-title":"Unusual cause of genetic refractory epilepsy due to NEXMIF gene (KIAA2022): Report of the first case in Argentina","volume":"60","author":"Appendino","year":"2019","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib3","first-page":"1","article-title":"Epilepsy and cannabidiol: a guide to treatment","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.seizure.2021.11.020","article-title":"High dose cannabidiol (CBD) in the treatment of new-onset refractory status epilepticus (NORSE)","volume":"94","author":"Aydemir","year":"2022","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107731_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.316","article-title":"A case of CHD2 epileptic encephalopathy","volume":"98","author":"Bone","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/epi.16480","article-title":"KCNT1-related epilepsy: an international multicenter cohort of 27 pediatric cases","volume":"61","author":"Borlot","year":"2020","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.eplepsyres.2026.107731_bib9","doi-asserted-by":"crossref","first-page":"e2.6","DOI":"10.1136\/jnnp-2022-abn2.103","article-title":"059 cannabidiol in refractory adult epilepsies: Broadening the Lennox-Gastaut phenotype","volume":"93","author":"Bose","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109245","article-title":"Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures","volume":"143","author":"Caraballo","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108451","article-title":"Status of epileptic spasms: A study of 21 children","volume":"126","author":"Caraballo","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib12","article-title":"Drug-resistant PPP3CA-related focal refractory epileptic encephalopathy responsive to vagal nerve stimulation","volume":"40","author":"Carvajal-Gonz\u00e1lez","year":"2023","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107278","article-title":"Unmet needs in epileptic encephalopathy with spike-and-wave activation in sleep: a systematic review","volume":"199","author":"Chapman","year":"2024","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107731_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"17 2","key":"10.1016\/j.eplepsyres.2026.107731_bib15","doi-asserted-by":"crossref","first-page":"0191","DOI":"10.1212\/WNL.0000000000201804","article-title":"Long-term cenobamate for uncontrolled focal seizures in patients living in a group home or with developmental disability (P4-1.006)","volume":"100","author":"Connor","year":"2023","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.eplepsyres.2026.107731_bib16","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ajhp\/zxaa268","article-title":"Warfarin dose adjustment required after cannabidiol initiation and titration","volume":"77","author":"Cortopassi","year":"2020","journal-title":"Am. J. HealthSyst. Pharm."},{"issue":"7_ement_1","key":"10.1016\/j.eplepsyres.2026.107731_bib17","article-title":"Highly purified cannabidiol (CBD) use and therapeutic drug monitoring in pregnancy: a case report (P4-1.012)","volume":"102","author":"Dadhich","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib18","doi-asserted-by":"crossref","DOI":"10.2174\/1874205X-v16-e2203290","article-title":"Cannabidiol successful therapy for developmental and epileptic encephalopathy related to CYFIP2.","volume":"16","author":"de G\u00f3es","year":"2022","journal-title":"Open Neurol. J."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114288","article-title":"Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery","volume":"360","author":"Del Pozo","year":"2023","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/epi4.12796","article-title":"Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome","volume":"9","author":"Desnous","year":"2024","journal-title":"Epilepsia Open"},{"issue":"21","key":"10.1016\/j.eplepsyres.2026.107731_bib21","doi-asserted-by":"crossref","first-page":"011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"20","key":"10.1016\/j.eplepsyres.2026.107731_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.seizure.2022.11.006","article-title":"Cannabidiol in refractory status epilepticus: a review of clinical experiences","volume":"103","author":"Duda","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2023.09.015","article-title":"Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex","volume":"112","author":"Espinosa-Jovel","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib27","unstructured":"European Medicines Agency. 2025. Epidyolex. Accessed 23 September 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex."},{"issue":"8","key":"10.1016\/j.eplepsyres.2026.107731_bib28","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.3390\/ijerph18083993","article-title":"Efficacy of phytocannabinoids in epilepsy treatment: novel approaches and recent advances","volume":"18","author":"Farrelly","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9126","article-title":"Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis","volume":"6","author":"Fazlollahi","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib30","article-title":"A case of clinical worsening after stereo-electroencephalographic-guided radiofrequency thermocoagulation in a patient with polymicrogyria","volume":"21","author":"Ferri","year":"2023","journal-title":"Epilepsy Behav. Rep."},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107731_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/epi4.12740","article-title":"Cannabidiol in the acute phase of febrile infection-related epilepsy syndrome (FIRES)","volume":"8","author":"Fetta","year":"2023","journal-title":"Epilepsia Open"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib33","first-page":"232","article-title":"Resolution of seizures and normalization of EEG after Initiation of CBD in a patient with Doose syndrome","volume":"15","author":"Gold","year":"2015","journal-title":"Epilepsy Curr."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107731_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.neurol.2024.03.004","article-title":"Epileptic encephalopathies and progressive neurodegeneration","volume":"180","author":"Guerrini","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1152\/physrev.00063.2021","article-title":"Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum","volume":"103","author":"Guerrini","year":"2023","journal-title":"Physiol. Rev."},{"issue":"9","key":"10.1016\/j.eplepsyres.2026.107731_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2020.103970","article-title":"Rare homozygous nonsense variant in AIMP1 causing Early Onset Epileptic Encephalopathy with Burst Suppression (EOEE-BS)","volume":"63","author":"Gupta","year":"2020","journal-title":"Eur. J. Med. Genet"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib37","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1073\/pnas.0914661107","article-title":"Endogenous cannabinoid signaling is essential for stress adaptation","volume":"107","author":"Hill","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"01","key":"10.1016\/j.eplepsyres.2026.107731_bib38","doi-asserted-by":"crossref","first-page":"044","DOI":"10.1055\/s-0043-57008","article-title":"Efficacy of cannabidiol in pediatric patients: postmarket experience at a single center","volume":"22","author":"Hovey","year":"2024","journal-title":"J. Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib39","first-page":"325","article-title":"Epilepsy and EEGs in Malan syndrome (Sotos syndrome 2)","volume":"37","author":"Hunter","year":"2020","journal-title":"J. Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib40","first-page":"35","article-title":"Cannibinoids as a treatment option in CASK associated epilepsy","volume":"64","author":"Johnston","year":"2022","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib41","first-page":"98","article-title":"Epileptic spasms and neurodevelopmental regression: A rare presentation of anti-NMDA receptor encephalitis (P9-8.003)","volume":"18","author":"Joseph","year":"2022","journal-title":"Neurology"},{"issue":"18-23","key":"10.1016\/j.eplepsyres.2026.107731_bib42","article-title":"Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome","volume":"71","author":"Kaplan","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"23","key":"10.1016\/j.eplepsyres.2026.107731_bib43","first-page":"S77","article-title":"Febrile infectious related epilepsy syndrome (FIRES) a description of two patients","volume":"86","author":"Kerashvili","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2020.04.015","article-title":"Efficacy of different treatment modalities for acute and chronic phases of the Febrile Infection-Related Epilepsy Syndrome: A systematic review","volume":"79","author":"Kessi","year":"2020","journal-title":"Seizure"},{"issue":"12","key":"10.1016\/j.eplepsyres.2026.107731_bib45","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/01.ccm.0000510526.32566.53","article-title":"1853: triple bromide therapy in a case of Lafora disease","volume":"44","author":"Kimler","year":"2016","journal-title":"Crit. Care Med"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109852","article-title":"About 1.5 million community-dwelling US adults with active epilepsy reported uncontrolled seizures in the past 12 months, and seizure control varied by annual family income\u2014National Health Interview Survey, United States 2021 and 2022","volume":"157","author":"Kobau","year":"2024","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107731_bib47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/epi4.12411","article-title":"Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy","volume":"5","author":"Kuchenbuch","year":"2020","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107731_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/epi4.12699","article-title":"Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study","volume":"8","author":"K\u00fchne","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jns.2019.10.1488","article-title":"Case series of 3 individuals of African descent with dentatorubral-pallidoluysian atrophy","volume":"405","author":"Kutz","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.eplepsyres.2026.107731_bib50","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1111\/bcp.15262","article-title":"Expert advice for prescribing cannabis medicines for patients with epilepsy\u2014drawn from the Australian clinical experience","volume":"88","author":"Lawson","year":"2022","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib51","first-page":"307","article-title":"Prospective, controlled trial of cannabadiol in a case of FIRES. Epilepsy Currents. 15, 534","volume":"3","author":"Lopez","year":"2015","journal-title":"Abstract"},{"issue":"11","key":"10.1016\/j.eplepsyres.2026.107731_bib52","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/1570159X21666230322143401","article-title":"Update on cannabidiol clinical toxicity and adverse effects: a systematic review","volume":"21","author":"Madeo","year":"2023","journal-title":"Cur. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107731_bib53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: A randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib54","first-page":"S70","article-title":"Cannabidiol as a novel treatment for Lafora Body disease\u2013a case report","volume":"86","author":"Nayak","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107297","article-title":"Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy","volume":"112","author":"Nenert","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.659543","article-title":"Epileptic phenotype and cannabidiol efficacy in a Williams\u2013Beuren syndrome patient with atypical deletion: a case report","volume":"12","author":"Nicotera","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib57","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., et al., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372, n71. https:\/\/doi:10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.735292","article-title":"Case report: Lennox\u2013Gastaut epileptic encephalopathy responsive to cannabidiol treatment associated with a novel de novo mosaic SHANK1 variant","volume":"12","author":"Paprocka","year":"2021","journal-title":"Front. Genet"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107474","article-title":"Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program","volume":"112","author":"Park","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"17 1","key":"10.1016\/j.eplepsyres.2026.107731_bib60","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1212\/WNL.0000000000206336","article-title":"Long-term effectiveness of cannabidiol (CBD) against focal-onset seizures in treatment-resistant epilepsies (TRE): experience from the Expanded Access Program (EAP) (S29.005)","volume":"102","author":"Park","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2024.02.004","article-title":"Real life retrospective study of cannabidiol therapy in alternating hemiplegia of childhood","volume":"49","author":"Patel","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107731_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neurol.2023.07.012","article-title":"High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies","volume":"180","author":"Perriguey","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.33588\/rn.6504.2016573","article-title":"Cannabidiol: its use in refractory epilepsies","volume":"65","author":"Pesantez-Rios","year":"2017","journal-title":"Rev. Neurol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2026.107731_bib64","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40261-022-01205-y","article-title":"Effects of cannabidiol on appetite and body weight: A systematic review","volume":"42","author":"Pinto","year":"2022","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpn.2019.12.024","article-title":"Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: an open-label, prospective, interventional study","volume":"25","author":"Poisson","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejpn.2022.01.008","article-title":"Is cannabidiol worth a trial in Rasmussen encephalitis","volume":"37","author":"Prager","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ebcr.2018.07.004","article-title":"Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus","volume":"10","author":"Rajaraman","year":"2018","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.586110","article-title":"Cannabidiol treatment for refractory epilepsies in pediatrics","volume":"11","author":"Raucci","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114237","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","volume":"359","author":"Reddy","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2024.01.010","article-title":"Purified cannabidiol as add-on therapy in children with treatment-resistant infantile epileptic spasms syndrome","volume":"115","author":"Reyes Valenzuela","year":"2024","journal-title":"Seizure"},{"issue":"8\u20139","key":"10.1016\/j.eplepsyres.2026.107731_bib72","first-page":"565","article-title":"A rare case of a UBA5-related disorder (early infantile epileptic encephalopathy type 44): Clinical findings and course","volume":"38","author":"Riel-Romero","year":"2023","journal-title":"J. Child Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib73","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/epi.17240","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Riney","year":"2022","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib74","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1089\/can.2022.0255","article-title":"Cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy","volume":"9","author":"Riva","year":"2024","journal-title":"Cannabis Cannabinoid Res"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14737175.2020.1741350","article-title":"Emerging treatments for progressive myoclonus epilepsies","volume":"20","author":"Riva","year":"2020","journal-title":"Expert Rev. Neurother."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107731_bib76","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ejpn.2019.08.001","article-title":"Centromedian thalamic nuclei deep brain stimulation and anakinra treatment for FIRES \u2013 two different outcomes","volume":"23","author":"Sa","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107731_bib77","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.pediatrneurol.2015.02.008","article-title":"Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report","volume":"52","author":"Saade","year":"2015","journal-title":"Pediatr. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","article-title":"Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: Results from an expanded access program in the US","volume":"33","author":"Sands","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib79","first-page":"98","article-title":"Patient diagnosed with epilepsy due to mutation in the CDKL5 gene treated with cannabidiol therapy","volume":"59","author":"Silveira","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"issue":"12","key":"10.1016\/j.eplepsyres.2026.107731_bib80","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/pharmaceutics14122598","article-title":"Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020\u20132022)","volume":"14","author":"Souza","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib81","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1684\/epd.2022.1435","article-title":"Non-convulsive status epilepticus in the setting of cannabidiol adjunctive therapy","volume":"24","author":"Tanwir","year":"2022","journal-title":"Epileptic Disord."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107731_bib83","first-page":"97","article-title":"The use of cannabidiol in FIRES","volume":"63","author":"Taylor","year":"2021","journal-title":"Dev. Med. Child Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107731_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.26815\/acn.2022.00269","article-title":"Clinical spectrum and treatment outcomes of patients with developmental and\/or epileptic encephalopathy with spike-and-wave activation in sleep","volume":"30","author":"Tchah","year":"2022","journal-title":"Ann. Child Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107731_bib85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib86","doi-asserted-by":"crossref","unstructured":"Thiele, E.A., Marsh, E.D., French, J.A., Mazurkiewicz-Beldzinska, M., Benbadis, S.R., Joshi, C.; GWPCARE4 Study Group., 2018. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 391 (10125), 1085\u20131096. https:\/\/doi:10.1016\/S0140-6736(18)30136-3.","DOI":"10.1016\/S0140-6736(18)30136-3"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pediatrneurol.2023.10.012","article-title":"Real-life experience with purified cannabidiol treatment for refractory epilepsy: A multicenter retrospective study","volume":"150","author":"Tzadok","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib88","unstructured":"U.S. Food and Drug Administration. Epidiolex\u00ae Prescribing Information. 2025. Accessed 22 Sep 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210365s023lbl.pdf."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib89","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.seizure.2020.06.012","article-title":"Plant derived versus synthetic cannabidiol: wishes and commitment of epilepsy patients","volume":"80","author":"von Wrede","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2026.107731_bib91","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.seizure.2021.09.016","article-title":"The spectrum of epilepsy in children with 15q13.3 microdeletion syndrome","volume":"92","author":"Whitney","year":"2021","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib92","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/epi.17237","article-title":"Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107731_bib93","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2023.08.033","article-title":"Quality of life in Angelman syndrome: A caregivers\u2019 survey","volume":"149","author":"Xia","year":"2023","journal-title":"Ped. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib94","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1684\/epd.2021.1338","article-title":"Exacerbation of eyelid myoclonia in patients with epilepsy and eyelid myoclonia receiving cannabidiol","volume":"23","author":"Zawar","year":"2021","journal-title":"Epileptic Disord."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107731_bib95","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"}],"updated-by":[{"DOI":"10.1016\/j.eplepsyres.2026.107777","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000}},{"DOI":"10.1016\/j.eplepsyres.2026.107777","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112600001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112600001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T10:26:17Z","timestamp":1775384777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012112600001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":95,"alternative-id":["S092012112600001X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107731","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107731"}}